The Mainz company has made its first strategic decision following the founders departure and will stick with mRNA technology.

Reported by AI Fact checked

A large retrospective study from the University of Florida and The University of Texas MD Anderson Cancer Center, published in Nature, reports that patients with advanced non-small cell lung cancer or metastatic melanoma lived significantly longer if they received a Pfizer-BioNTech or Moderna COVID-19 mRNA shot within 100 days of starting immune checkpoint inhibitors. The authors stress the findings are observational and will require confirmation in randomized trials.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline